Amneal Nordic

Amneal Nordic was the Nordic regional subsidiary of Amneal focused on commercializing generic pharmaceutical products. The entity appears to have operated as a local commercial affiliate in Denmark serving Nordic markets rather than as an R&D-driven biotechnology company. In Amneal's 2017 financial reporting, the company disclosed that it sold the stock, certain marketing authorizations, and associated dossiers of Amneal Nordic ApS and Amneal Pharma Spain S.L. to Aristo Pharma GmbH on December 31, 2017. As a result, Amneal Nordic should be viewed as a former Amneal operating subsidiary rather than an active standalone biotech or pharma innovator today. Its business profile was centered on marketed generic medicines, regional commercialization, and product registrations.